0000000001078309

AUTHOR

Soledad Herrero

showing 2 related works from this author

Can a healthy life prevent us from post-menopausal osteoporosis? Myths and truths

2016

Abstract Postmenopausal osteoporosis is related to unmodifiable risk factors (genetics, race, gender and age). However, other controllable factors such as activity, body mass, hormone and calcium levels and dietary habits can reduce fracture risk. For example, significant increases in bone mass density have been linked to physical activity in children, supplements of Vitamin C taken for more than 10 years, or high consumption of fish, olive oil or dried plums. This review establishes the scientific basis behind these non-pharmaceutical practices and summarizes a number of basic studies and clinical trials involving them as well as discusses their potential for the osteoporosis treatment. A …

0301 basic medicinemedicine.medical_specialtyOsteoporosisPhysiology030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEpidemiologyMedicinePharmacology (medical)Adverse effectPharmacology030109 nutrition & dieteticsVitamin Cbusiness.industryIsoflavonesmedicine.diseaseClinical trialEndocrinologychemistryOvariectomized ratBiomarker (medicine)businessFood SciencePharmaNutrition
researchProduct

Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

2016

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopaus…

0301 basic medicinemedicine.medical_specialtyLong term treatmentTime Factorsmedicine.medical_treatmentRomosozumab030209 endocrinology & metabolismPostmenopausal osteoporosisBone resorption03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectOsteoporosis PostmenopausalPharmacologybusiness.industryPublic healthBisphosphonateSurgery030104 developmental biologyDenosumabFemalebusinessmedicine.drugEuropean journal of pharmacology
researchProduct